170 related articles for article (PubMed ID: 11999466)
1. Long-term safety and efficacy of a once-daily formulation of alfuzosin 10 mg in patients with symptomatic benign prostatic hyperplasia: open-label extension study.
van Kerrebroec P; Jardin A; van Cangh P; Laval KU;
Eur Urol; 2002 Jan; 41(1):54-60; discussion 60-1. PubMed ID: 11999466
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of a new prolonged release formulation of alfuzosin 10 mg once daily versus alfuzosin 2.5 mg thrice daily and placebo in patients with symptomatic benign prostatic hyperplasia. ALFORTI Study Group.
van Kerrebroeck P; Jardin A; Laval KU; van Cangh P
Eur Urol; 2000 Mar; 37(3):306-13. PubMed ID: 10720857
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of once-daily alfuzosin in the treatment of lower urinary tract symptoms and clinical benign prostatic hyperplasia: a randomized, placebo-controlled trial.
Roehrborn CG
Urology; 2001 Dec; 58(6):953-9. PubMed ID: 11744466
[TBL] [Abstract][Full Text] [Related]
4. Alfuzosin: a review of the therapeutic use of the prolonged-release formulation given once daily in the management of benign prostatic hyperplasia.
McKeage K; Plosker GL
Drugs; 2002; 62(4):633-53. PubMed ID: 11893233
[TBL] [Abstract][Full Text] [Related]
5. Safety and efficacy of alfuzosin 10 mg once-daily in the treatment of lower urinary tract symptoms and clinical benign prostatic hyperplasia: a pooled analysis of three double-blind, placebo-controlled studies.
Roehrborn CG; Van Kerrebroeck P; Nordling J
BJU Int; 2003 Aug; 92(3):257-61. PubMed ID: 12887479
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of two doses (10 and 15 mg) of alfuzosin or tamsulosin (0.4 mg) once daily for treating symptomatic benign prostatic hyperplasia.
Nordling J
BJU Int; 2005 May; 95(7):1006-12. PubMed ID: 15839922
[TBL] [Abstract][Full Text] [Related]
7. Alfuzosin 10 mg once daily for treating benign prostatic hyperplasia: a 3-year experience in real-life practice.
Vallancien G; Emberton M; Alcaraz A; Matzkin H; van Moorselaar RJ; Hartung R; Harving N; Elhilali M;
BJU Int; 2008 Apr; 101(7):847-52. PubMed ID: 18321317
[TBL] [Abstract][Full Text] [Related]
8. Clinical uroselectivity: evidence from patients treated with slow-release alfuzosin for symptomatic benign prostatic obstruction.
Buzelin JM; Delauche-Cavallier MC; Roth S; Geffriaud-Ricouard C; Santoni JP
Br J Urol; 1997 Jun; 79(6):898-904; discussion 904-6. PubMed ID: 9202556
[TBL] [Abstract][Full Text] [Related]
9. Alfuzosin: a clinically uroselective alpha1-blocker.
Höfner K; Jonas U
World J Urol; 2002 Apr; 19(6):405-12. PubMed ID: 12022709
[TBL] [Abstract][Full Text] [Related]
10. The efficacy and safety of a new once-a-day formulation of an alpha-blocker.
Van Kerrebroeck PE
Eur Urol; 2001 Mar; 39 Suppl 6():19-26. PubMed ID: 11306897
[TBL] [Abstract][Full Text] [Related]
11. Clinical uroselectivity of alfuzosin in the treatment of benign prostatic hyperplasia.
Kirby RS
Eur Urol; 1998; 33 Suppl 2():19-27. PubMed ID: 9556192
[TBL] [Abstract][Full Text] [Related]
12. Safety and efficacy of sustained-release alfuzosin on lower urinary tract symptoms suggestive of benign prostatic hyperplasia in 3,095 Spanish patients evaluated during general practice.
Sánchez-Chapado M; Guil M; Alfaro V; Badiella L; Fernández-Hernando N
Eur Urol; 2000 Apr; 37(4):421-7. PubMed ID: 10765072
[TBL] [Abstract][Full Text] [Related]
13. Sustained-release alfuzosin, finasteride and the combination of both in the treatment of benign prostatic hyperplasia. European ALFIN Study Group.
Debruyne FM; Jardin A; Colloi D; Resel L; Witjes WP; Delauche-Cavallier MC; McCarthy C; Geffriaud-Ricouard C
Eur Urol; 1998 Sep; 34(3):169-75. PubMed ID: 9732187
[TBL] [Abstract][Full Text] [Related]
14. Long-term efficacy and safety of alfuzosin 10 mg once daily: a 2-year experience in 'real-life' practice.
Elhilali M; Emberton M; Matzkin H; van Moorselaar RJ; Hartung R; Harving N; Alcaraz A; Vallancien G;
BJU Int; 2006 Mar; 97(3):513-9. PubMed ID: 16469018
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of sustained-release alfuzosin 5 mg in patients with benign prostatic hyperplasia. ALGEBI Study Group.
Buzelin JM; Roth S; Geffriaud-Ricouard C; Delauche-Cavallier MC
Eur Urol; 1997; 31(2):190-8. PubMed ID: 9076465
[TBL] [Abstract][Full Text] [Related]
16. First dose efficacy of alfuzosin once daily in men with symptomatic benign prostatic hyperplasia.
Marks LS; Roehrborn CG; Gittelman M; Kim D; Forrest J; Jacobs S
Urology; 2003 Nov; 62(5):888-93. PubMed ID: 14624914
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of alfuzosin 10 mg once daily in the treatment of symptomatic benign prostatic hyperplasia.
Kuritzky L; Rosenberg MT; Sadovsky R
Int J Clin Pract; 2006 Mar; 60(3):351-8. PubMed ID: 16494652
[TBL] [Abstract][Full Text] [Related]
18. Alfuzosin: overview of pharmacokinetics, safety, and efficacy of a clinically uroselective alpha-blocker.
Roehrborn CG
Urology; 2001 Dec; 58(6 Suppl 1):55-63; discussion 63-4. PubMed ID: 11750253
[TBL] [Abstract][Full Text] [Related]
19. Alfuzosin 10 mg once daily prevents overall clinical progression of benign prostatic hyperplasia but not acute urinary retention: results of a 2-year placebo-controlled study.
Roehrborn CG
BJU Int; 2006 Apr; 97(4):734-41. PubMed ID: 16536764
[TBL] [Abstract][Full Text] [Related]
20. Alfuzosin hydrochloride for the treatment of benign prostatic hyperplasia.
Lee M
Am J Health Syst Pharm; 2003 Jul; 60(14):1426-39. PubMed ID: 12892027
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
